CA3231700A1 - Fatty acid conjugates of nucleic acids - Google Patents

Fatty acid conjugates of nucleic acids Download PDF

Info

Publication number
CA3231700A1
CA3231700A1 CA3231700A CA3231700A CA3231700A1 CA 3231700 A1 CA3231700 A1 CA 3231700A1 CA 3231700 A CA3231700 A CA 3231700A CA 3231700 A CA3231700 A CA 3231700A CA 3231700 A1 CA3231700 A1 CA 3231700A1
Authority
CA
Canada
Prior art keywords
fatty acid
group
acid moiety
conjugate
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231700A
Other languages
English (en)
French (fr)
Inventor
Shuhao Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guardian Therapeutics LLC
Original Assignee
Guardian Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guardian Therapeutics LLC filed Critical Guardian Therapeutics LLC
Publication of CA3231700A1 publication Critical patent/CA3231700A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3231700A 2021-09-10 2022-09-09 Fatty acid conjugates of nucleic acids Pending CA3231700A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163242679P 2021-09-10 2021-09-10
US63/242,679 2021-09-10
PCT/US2022/076198 WO2023039522A1 (en) 2021-09-10 2022-09-09 Fatty acid conjugates of nucleic acids

Publications (1)

Publication Number Publication Date
CA3231700A1 true CA3231700A1 (en) 2023-03-16

Family

ID=83508900

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231700A Pending CA3231700A1 (en) 2021-09-10 2022-09-09 Fatty acid conjugates of nucleic acids

Country Status (6)

Country Link
US (1) US20240247274A1 (cg-RX-API-DMAC7.html)
EP (1) EP4398939A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024533427A (cg-RX-API-DMAC7.html)
CN (1) CN117980003A (cg-RX-API-DMAC7.html)
CA (1) CA3231700A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023039522A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11060094B2 (en) * 2017-05-19 2021-07-13 Band Therapeutics, Llc Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor
JP7699856B2 (ja) * 2021-03-25 2025-06-30 アプタキュア セラピューティクス リミテッド in vivo半減期が延長された核酸分子コンジュゲート
WO2025140190A1 (en) * 2023-12-25 2025-07-03 Microbio (Shanghai) Co., Ltd. Carbon chain-modified nucleic acids and uses thereof for bacterial cell delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CA3057292A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified oligonucleotides and therapeutic uses thereof
WO2021046497A2 (en) * 2019-09-06 2021-03-11 Shen Haifa Orally delivered therapeutical composition and use thereof
CN115397471B (zh) * 2019-11-26 2026-01-23 诺华股份有限公司 包括核酸和半衰期延长基序的化合物
EP4100121A4 (en) * 2020-02-04 2024-04-10 Band Therapeutics, LLC REGULATION OF THE VON WILLEBRAND FACTOR (VWF)
EP4213883A1 (en) * 2020-09-16 2023-07-26 Astrazeneca AB Oligonucleotides conjugated to fatty acids
WO2023009529A2 (en) * 2021-07-28 2023-02-02 Trustees Of Boston University Novel polypeptides and uses thereof

Also Published As

Publication number Publication date
WO2023039522A1 (en) 2023-03-16
CN117980003A (zh) 2024-05-03
US20240247274A1 (en) 2024-07-25
EP4398939A1 (en) 2024-07-17
JP2024533427A (ja) 2024-09-12

Similar Documents

Publication Publication Date Title
US20240247274A1 (en) Fatty acid conjugates of nucleic acids
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
JP2024023899A (ja) アンチセンス核酸
JP2025120251A (ja) 治療化合物用の標的化リガンド
KR102473431B1 (ko) 안티센스 핵산
CN119213123A (zh) Lpa抑制剂及其用途
JP7183167B2 (ja) 減少した腎クリアランスを有する多量体オリゴヌクレオチド
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
CN110951732A (zh) 反义核酸
JP2008512097A (ja) アプタマー医薬品化学
JP7777522B2 (ja) ベータENaCの発現を阻害するRNAi剤、その組成物および使用方法
TW201446791A (zh) 用於調節mir-122之微小rna化合物及方法
KR20220019255A (ko) 알파-1 항트립신 결핍증 (aatd)의 치료 방법
TW202405174A (zh) 用於抑制超氧化物歧化酶1(SOD1)表現之RNAi藥劑、其組合物及使用方法
US20250034578A1 (en) Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products
CN119768186A (zh) 用于向cns组织递送治疗剂的脂质缀合物
CN114555188A (zh) 治疗apoc3相关疾病和病症的方法
CN111212909A (zh) 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
CN117187242A (zh) 一种siRNA及其缀合物
KR20240014067A (ko) 뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
CN116670278A (zh) 用于降低z-aat蛋白水平的方法
WO2020044349A1 (en) Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules
CN121152878A (zh) 用于抑制补体因子B (CFB)表达的RNAi剂、其药物组合物和使用方法
WO2025031302A1 (zh) 靶向pd-l1的双链核糖核酸
KR20250099175A (ko) 보체 성분 C3 (C3)의 발현을 억제하기 위한 RNAi 작용제, 그의 제약 조성물, 및 사용 방법